免疫检查点抑制剂治疗EGFR突变晚期非小细胞肺癌经EGFR酪氨酸激酶抑制剂进展后的疗效与安全性:系统评价、Meta分析与网络Meta分析
该系统评价与Meta分析纳入17项单臂试验和15项随机对照试验共2886例经EGFR-TKI进展的晚期EGFR突变NSCLC患者,比较七种含免疫检查点抑制剂(ICI)策略。配对Meta分析显示ICI单药较化疗无进展生存期缩短(HR 1.73),ICI联合抗血管生成及化疗(HR 0.54)与ICI联合化疗(HR 0.77)延长无进展生存期。网络Meta分析显示ICI联合抗血管生成及化疗的无进展生存期最佳,但任何级别及3级及以上不良事件风险较高。
要点
- ICI联合抗血管生成及化疗在网络Meta分析中无进展生存期最佳(HR 0.30 vs ICI单药,HR 0.71 vs ICI联合化疗)。
- ICI单药较化疗无进展生存期更短(HR 1.73,95%CI 1.30-2.29)。
- ICI联合抗血管生成及化疗的任何级别及3级及以上不良事件风险高于ICI联合化疗和化疗。
核心结论
- 对于经EGFR-TKI进展的晚期EGFR突变NSCLC患者,ICI联合抗血管生成及化疗被确定为最佳治疗选择。
- 该治疗毒性可接受但需密切关注。
- ICI联合化疗疗效明显优于标准治疗化疗。
- 这些发现阐明了含ICI治疗策略在难治性人群中的作用,可能补充近期指南。
研究设计与样本
- 系统评价、Meta分析与网络Meta分析,采用单臂、配对和网络Meta分析方法。
- 检索PubMed、Embase、Cochrane Library、Web of Science、ClinicalTrials.gov及相关国际会议论文集,从数据库建库至2024年1月31日,无语言限制。
- 纳入17项单臂试验和15项随机对照试验,共2886例参与者,评估七种含ICI治疗策略。
- 纳入标准为组织学或细胞学确诊的晚期EGFR突变NSCLC、至少一种EGFR-TKI治疗后进展、评估至少一项临床结局的已发表或未发表1、2或3期临床试验。
- 主要分析结局为无进展生存期;方案注册于PROSPERO,CRD42021292626。
主要发现
- 配对Meta分析显示,与化疗相比,ICI单药导致无进展生存期缩短(HR 1.73 [95%CI 1.30-2.29],I²=0%)。
- 配对Meta分析显示,ICI联合抗血管生成及化疗(HR 0.54 [95%CI 0.44-0.67],I²=0%)和ICI联合化疗(HR 0.77 [95%CI 0.67-0.88],I²=0%)延长无进展生存期。
- 网络Meta分析显示,ICI联合抗血管生成及化疗较ICI联合化疗(HR 0.71 [95%可信区间 0.59-0.85])、ICI单药(HR 0.30 [95%可信区间 0.22-0.41])、抗血管生成联合化疗(HR 0.76 [95%可信区间 0.58-1.00])和单纯化疗(HR 0.54 [95%可信区间 0.45-0.64])均有显著获益。
- 网络Meta分析显示,ICI联合抗血管生成及化疗较ICI联合化疗和化疗与任何级别及3级或更差不良事件风险升高相关。
关键数值与推荐
- 七种含ICI策略:ICI单药、ICI联合化疗、ICI联合抗血管生成、ICI联合抗血管生成及化疗、双ICI、双ICI联合化疗、ICI联合EGFR-TKI。
- ICI单药、ICI联合抗血管生成及化疗、ICI联合化疗三种策略有足够数据行配对Meta分析。
- ICI联合抗血管生成及化疗在无进展生存期方面优于ICI联合化疗(HR 0.71 [95%可信区间 0.59-0.85])。
- ICI联合抗血管生成及化疗在无进展生存期方面优于ICI单药(HR 0.30 [95%可信区间 0.22-0.41])。
- ICI联合抗血管生成及化疗在无进展生存期方面优于单纯化疗(HR 0.54 [95%可信区间 0.45-0.64])。
临床怎么用
- 作者认为,对于经EGFR-TKI进展的晚期EGFR突变NSCLC患者,ICI联合抗血管生成及化疗是最佳治疗选择。
- 作者指出,该治疗毒性可接受但需密切关注。
- 作者认为,ICI联合化疗疗效明显优于标准治疗化疗。
- 原文未据此给出具体推荐等级。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The clinical benefits of immune checkpoint inhibitor (ICI)-based treatments in treating individuals with advanced EGFR-mutated non-small-cell lung cancer (NSCLC) who have progressed on EGFR tyrosine-kinase inhibitors (TKIs) remain controversial. We aimed to review the literature to comprehensively investigate the individual and comparative clinical outcomes of various ICI-based treatment strategies in this population. METHODS: In this systematic review and meta-analysis, we used single-arm, pairwise, and network meta-analytical approaches. We searched PubMed, Embase, Cochrane Library, Web of Science, ClinicalTrials.gov, and relevant international conference proceedings from database inception to Jan 31, 2024, without language restrictions, to identify eligible clinical trials that assessed ICI-based treatments for individuals with advanced EGFR-mutated NSCLC who progressed on EGFR-TKIs. Studies considered eligible were published and unpublished phase 1, 2, or 3 clinical trials enrolling participants with histologically or cytologically confirmed advanced EGFR-mutated NSCLC who had progressed after at least one EGFR-TKI treatment, and that evaluated ICI-based treatment strategies on at least one of the clinical outcomes of interest. The primary outcome analysed was progression-free survival. The protocol is registered with PROSPERO, CRD42021292626. FINDINGS: 17 single-arm trials and 15 randomised controlled trials, involving 2886 participants and seven ICI-based treatment strategies (ICI monotherapy, ICI plus chemotherapy [ICI-chemo], ICI plus antiangiogenesis [ICI-antiangio], ICI plus antiangiogenesis plus chemotherapy [ICI-antiangio-chemo], dual ICIs [ICI-ICI], dual ICIs plus chemotherapy [ICI-ICI-chemo], and ICI plus EGFR-TKI [ICI-TKI]), were included. Three of these strategies-ICI monotherapy, ICI-antiangio-chemo, and ICI-chemo-had sufficient data across the included studies to perform a pairwise meta-analysis. The pairwise meta-analysis showed that, compared with chemotherapy, ICI monotherapy led to shorter progression-free survival (hazard ratio [HR] 1·73 [95% CI 1·30-2·29], I2=0%), whereas ICI-antiangio-chemo (HR 0·54 [0·44-0·67], I2=0%) and ICI-chemo (HR 0·77 [0·67-0·88], I2=0%) prolonged progression-free survival. The network meta-analysis showed that ICI-antiangio-chemo yielded the best progression-free survival results, with substantial benefits over ICI-chemo (HR 0·71 [95% credible interval 0·59-0·85]), ICI monotherapy (HR 0·30 [0·22-0·41]), and non-ICI treatment strategies including antiangio-chemo (HR 0·76 [0·58-1·00]) and chemotherapy alone (HR 0·54 [0·45-0·64]). ICI-antiangio-chemo was associated with higher risks of both any-grade and grade 3 or worse adverse events over ICI-chemo and chemotherapy in the network meta-analysis. INTERPRETATION: For individuals with advanced EGFR-mutated NSCLC who progressed on EGFR-TKIs, ICI-antiangio-chemo was identified as the optimal treatment option. The toxicity of this treatment was acceptable but needs careful attention. ICI-chemo showed appreciably greater efficacy than the standard-of-care chemotherapy. These findings clarified the roles of ICI-based treatment strategies in this difficult-to-treat refractory population, potentially complementing recent guidelines. FUNDING: None.
引用
- Zhao Y, He Y, Wang W, et al. Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis. Lancet Oncol. 2024. PMID: 39159630. doi:10.1016/S1470-2045(24)00379-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。